Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Have a body mass index (BMI) of ≤ 30.0 kg/m2 at screening and at admission.
Part B:
Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Chronic hepatitis delta (CHD) for ≥ 6 months prior to screening, documented by prior medical history.
Must be receiving a commercially available entecavir, TAF, or TDF for the treatment of hepatitis B virus (HBV) infection at or prior to enrollment. Coformulation as part of a fixed-dose combination for the treatment of HIV is permitted.
Alanine aminotransferase (ALT) level \> 1 × Upper limit of normal (ULN), but \< 10 × ULN at screening.
You may not be if
Part A:
Positive serum or urine pregnancy test.
Participants with plans to breastfeed during the study period.
Part B:
Positive serum or urine pregnancy test.
Participants with plans to breastfeed during the study period.
Current or previous clinically decompensated liver disease, including coagulopathy, hepatic encephalopathy, and esophageal varices hemorrhage due to HDV or HBV.
Child-Turcotte-Pugh (CTP)-B or -C or a CTP score of ≥ 7.
